ClexBio is a biotechnology company specializing in tissue therapy and the development of bioengineered tissues. The company uses VivoSet™ technology to produce fully vascularized therapeutic tissues without the use of artificial materials. This approach ensures better integration with the host environment, which is essential for effective treatment.
ClexBio focuses on the targeted treatment of several serious conditions, including type 1 diabetes, advanced liver disease and heart disease. The company's solutions include function-specific therapeutic cells in a holistic multicellular architecture, enabling rapid engraftment and anastomosis with the host's vasculature. ClexBio combines advanced microfluidics with proprietary hydrogel technology to create ground-breaking solutions in tissue technology and single-cell methods.
